The present invention relates to a process for the preparation of 1- (2-ethoxyethyl) -5- (ethyl (methyl) amino) -7- (4-methylpyridin- (ESRD) in a patient, comprising administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of: <； RTI ID = 0.0 >； [4, 3-d] pyrimidine-3-carboxamide. The invention also includes administration of a pharmaceutical composition to delay progression to ESRD. - (4-methylpyridin-2-yl) amino) -N- (methylsulfonyl) -lH-pyrazolo [4 , 3-d] pyrimidine-3-carboxamide본 발명은 1-(2-에톡시에틸)-5-(에틸(메틸)아미노)-7-((4-메틸피리딘-2-일)아미노)-N-(메틸술포닐)-1H-피라졸로[4,3-d]피리미딘-3-카르복스아미드의 투여를 포함하는, 환자에서 말기 신질환 (ESRD)의 진행을 지연시키는 방법에 관한 것이다. 본 발명은 또한 ESRD로의 진행을 지연시키기 위한 제약 조성물의 투여를 포함한다.1-(2-에톡시에틸)-5-(에틸(메틸)아미노)-7-((4-메틸피리딘-2-일)아미노)-N-(메틸술포닐)-1H-피라졸로[4,3-d]피리미딘-3-카르복스아미드
